Category Pharmaceuticals
L’intelligence artificielle du point de vue de la santé globale
Vincent Couture et Jean-Christophe Bélisle-Pipon explorent les nouvelles menaces existentielles qu’engendre l’intelligence artificielle restreinte et générale pour la santé mondiale et proposent des stratégies pour s’y attaquer.
Psychedelics, Ethics, and the Commercial Determinants of Health
Daniel Rosenbaum and Daniel Z. Buchman draw attention to commercial involvement in psychedelic research and to the population health risks associated with this involvement.
Alberta’s Recovery-Based Approach to the Opioid Crisis
Shyanne Dougherty questions the goal and the likely effectiveness of the Alberta UCP government’s supposed “recovery-based” approach to the opioid crisis.
Mind the Ethical Gap in AI-Powered Drug Discovery
Dessislava Fessenko shows that while artificial intelligence might revolutionize drug development, its use comes with risks and potential ethical implications. Iterative ethics oversight from the get-go is needed to address the looming concerns.
Independence, Influence & Power: Canada’s Failed Medicine Pricing Reforms
Matthew Herder presents his opening statement to the House of Commons’ Standing Committee on Health on May 2, 2023. In February, Herder resigned from the Patented Medicine Prices Review Board (PMPRB).
Impact Ethics 